CLAIMS

1. Use of azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for the manufacture of a medicament for the treatment of sudden sensorineural hearing loss (SSNHL) in a subject in need thereof, wherein the subject suffers from severe or profound SSNHL associated with at least one of:

- a hearing threshold at baseline corresponding to a pure tone audiometry (PTA) at baseline equal to or greater than 70 dB;
- a hearing loss at baseline equal to or greater than 91 dB corresponding to a profound hearing loss according to the American Speech-Language-Hearing Association (ASHA) classification;
- a hearing loss at baseline affecting frequencies equal to or lower than 2000 Hz; and/or
- the presence of vertigo at baseline.

2. The use according to claim **1**, wherein the subject suffers from severe or profound SSNHL associated with a hearing threshold at baseline corresponding to a PTA at baseline equal to or greater than 80 dB.

3. The use according to claim **1** or **2**, wherein the subject suffers from severe or profound SSNHL associated with a hearing threshold at baseline corresponding to a PTA at baseline equal to or greater than 90 dB.

4. The use according to any one of claims **1** to **3**, wherein the subject suffers from severe or profound SSNHL associated with a hearing loss at baseline affecting frequencies equal to or lower than 2000 Hz.

5. The use according to any one of claims **1** to **4**, wherein SSNHL is idiopathic SSNHL.

6. The use according to any one of claims **1** to **5**, wherein SSNHL is unilateral.

7. The use according to any one of claims **1** to **6**, wherein azasetron is (*R*)-azasetron, (*S*)-azasetron, a mixture thereof, or a pharmaceutically acceptable salt and/or solvate thereof.

8. The use according to any one of claims **1** to **7**, wherein azasetron is (*R*)-azasetron or a pharmaceutically acceptable salt and/or solvate thereof.

9. The use according to any one of claims **1** to **8**, wherein the pharmaceutically acceptable salt is selected from a besylate salt, a malate salt, and a hydrochloride salt.

10. The use according to any one of claims **1** to **9**, wherein the pharmaceutically acceptable salt is (*R*)-azasetron besylate.

11. The use according to any one of claims **1** to **10**, wherein the analog of azasetron is a benzoxazine compound or a pharmaceutically acceptable salt and/or solvate thereof.

12. The use according to any one of claims **1** to **11**, wherein the analog of azasetron is selected from 6-chloro-3,4-dihydro-2-methyl-3-oxo-N-(3-quinuclidinyl)-2H-1,4-benzoxazine-8-carboxamide, 6-chloro-3,4-dihydro-2,4-dimethyl-3-oxo-N-(3-quinuclidinyl)-2H-benzoxazine-8-carboxamide, 6-chloro-2-ethyl-3,4-dihydro-4-methyl-3-oxo-N-(3-quinuclidinyl)-2H-1,4-benzoxazine-8-carboxamide, 6-chloro-3,4-dihydro-4-methyl-3-oxo-N-(3-quinuclidinyl)-2H-1,4-benzoxazine-8-carboxamide, 6-bromo-3,4-dihydro-2,4-dimethyl-3-oxo-N-(3-quinuclidinyl)-2H-1,4-benzoxazine-8-carboxamide, 6-chloro-3,4-dihydro-2,2,4-trimethyl-3-oxo-N-(3-quinuclidiny-l)-2H-1,4-benzoxazine-8-carboxamide, and pharmaceutically acceptable salts and/or solvates thereof.

13. The use according to any one of claims **1** to **12**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is to be administered at a daily dose ranging from about 20 mg to about 200 mg.

14. The use according to any one of claims **1** to **13**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is to be administered at a daily dose of about 40 mg or of about 60 mg.

15. The use according to any one of claims **1** to **14**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is to be administered within about 96 hours from the first onset of SSNHL.

16. The use according to any one of claims **1** to **15**, wherein azasetron or the analog of azasetron, or the pharmaceutically acceptable salt and/or solvate thereof, is to be administered with at least one further pharmaceutically active agent.

17. The use according to claim **16**, wherein the at least one further pharmaceutically active agent is a corticosteroid.